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Wnt/β-catenin (Wnt) signalling is involved in cancer cell self-renewal, epidermal to 
mesenchymal transition and growth signalling. Furthermore the interplay between Wnt pathway 
components and androgen receptor (AR) signalling have been well documented [1]. Linkage 
studies in prostate cancer have demonstrated an association between Wnt pathway genes and 
reduced PSA-free survival [2] and prostate cancer progression [3]. RNA-Sequencing of 
circulating tumour cells has implicated non-canonical Wnt pathway activation in resistance to 
AR antagonism [4] and large scale sequencing efforts have revealed genomic aberrations in 
the Wnt signalling pathway in approximately 20% of castration-resistant prostate cancer 
(CRPC) metastases obtained by biopsy or at rapid autopsy [5, 6]. In this edition of Annals of 
Oncology, Wang et al report the PROMOTE single-centre trial designed to identify associations 
with primary resistance to abiraterone using molecular analyses of tumor biopsies obtained 
prior to treatment from progressing pre-chemotherapy metastatic CRPC patients [7]. This 
prospectively defined and well-characterised study population is an important resource. 
Specifically, Wang et al enrolled 92 men and succeeded in performing a combination of whole 
exome and/or whole transcriptome sequencing on tumours from 86. Of note, 72% of biopsies 
were from bone metastases, putatively more clinically representative than most recent 
endeavours that were enriched for soft tissue disease. Patients were dichotomised by 
progression at 12 weeks of therapy  (non-responders vs responders) and associations with 
mutated genes, copy number aberrations and transcriptional profiles were determined. For 
these analyses, the authors selected 98 genes with recurrent mutations in two or more tumours 
in their and the Grasso and Robinson data sets. They also restricted copy number evaluation 
to tumours with a minimum 15% tumour purity and transcriptomic analyses to skeletal 
metastases. Activating mutations in the Wnt pathway were enriched in abiraterone non-
responders compared to responders (56.3 vs 17.1%, p=0.001) and patients were twice as likely 
(HR 2.07, CI 1.08-3.97, p=0.03) to be resistant to abiraterone if they had gene expression 
aberrations of the pathway. 
 
Another strength of the current study is that the investigators functionally tested chemical 
inhibition of Wnt signalling in combination with abiraterone in abiraterone-sensitive and 
resistant patient-derived prostate cancer organoids. In keeping with their prediction, inhibition 
of Wnt had little effect in the abiraterone-sensitive (normal Wnt) model but in the abiraterone-






























































resistant model (aberrant Wnt), cell death was seen with Wnt inhibitor monotherapy and partial 
induction of sensitivity when combined with abiraterone. Future work could further support the 
association between aberrant Wnt signalling and abiraterone resistance using an orthogonal 
approach such as CRISPR-CASP9 genome editing to activate the Wnt pathway. It should also 
be noted that abiraterone may be acting as an AR antagonist in in vitro models, rather than by 
inhibiting androgen synthesis [8], in this case also competing with pregnenolone added as a 
CYP17 substrate. These findings nonetheless still implicate Wnt pathway signalling in 
resistance to AR inhibition. The results of drug screens in organoid or patient-derived xenograft 
models have been correlated with clinical responses [9, 10], but the lack of stromal and 
immunological interactions are a limitation that could be overcome by developing co-culture 
systems or using the next generation of humanised mouse models.  
 
Low tumour purity can markedly reduce the detection of mutations and copy number changes 
in clinical samples. Traditional visual or image analysis of tumour purity is being replaced by 
computational methods. In the current study, the inferred tumour purity was low (median 33%) 
although the high mean sequencing coverage of 258x should help to limit the false negative 
rate.  Low tumour purity has previously been correlated to some clinicopathological entities in 
prostate cancer [11] and Wang et al build on this by presenting a trend to higher tumour purity 
in non-responders compared to responders (36% vs 22%, p=0.09). Low tumour purity implies 
that non-tumour cells or tumour microenviroment (TME) predominates in the sample.  It is well 
recognised that paracrine Wnt signals from the TME can contribute to prostate tumour 
progression [4]. In mouse models, Wnt signalling has been implicated as modulating the TME- 
inflammatory response, [12] and similarly, we have recently demonstrated in a cohort of high-
risk localised or hormone-naïve metastatic prostate cancer patients that activated Wnt 
signalling correlated with low CD8/FoxP3 ratio, consistent with a dysfunctional T-cell response 
and tumour escape[13]. 
 
While a convincing association between Wnt signalling and abiraterone primary resistance is 
reported in this discovery cohort, the negative predictive value, even if confirmed in 
independent validation sets, is insufficient for clinical decision making. Moreover, nearly one-in-
five Wnt aberrant patients responded. Prostate cancer mouse models suggest that Wnt/β-
catenin signalling requires additional events (for example PTEN loss) for oncogenesis [14] and 
similarly, abiraterone resistance may also be multi-genomic. AR aberrations detected in blood, 
both genomic (copy number gain or point mutations) and splice variants (mRNA or protein), 
have shown strong associations with primary resistance [15-17].  In the current study, tumour 
biopsy AR-V7 transcript levels also associated with primary resistance. It is therefore probable 
that a biomarker suite would provide the most accurate prediction of response. Overall, the 
PROMOTE data provide a strong rationale for testing of Wnt inhibitors (several agents 
currently in early clinical trial testing) alone or in combination with abiraterone in abiraterone-
resistant biomarker-selected patients.  
 
Conflict of Interest Disclosures 
The ICR developed abiraterone and therefore has a commercial interest in this agent. G.A. is 
on the ICR list of rewards to inventors for abiraterone. M.L. has received educational grants 






























































from BMS & Sanofi, travel support from Janssen, Astellas, Bayer and MSD and honorarium 
from Janssen. G.A. has received honoraria, consulting fees or travel support from Astellas, 
Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, ESSA Pharmaceuticals 






1. Murillo-Garzon V, Kypta R. WNT signalling in prostate cancer. Nat Rev 
Urol 2017; 14: 683-696. 
2. Huang SP, Ting WC, Chen LM et al. Association analysis of Wnt pathway 
genes on prostate-specific antigen recurrence after radical prostatectomy. Ann 
Surg Oncol 2010; 17: 312-322. 
3. Geng JH, Lin VC, Yu CC et al. Inherited Variants in Wnt Pathway Genes 
Influence Outcomes f Prostate Cancer Patients Receiving Androgen Deprivation 
Therapy. Int J Mol Sci 2016; 17. 
4. Miyamoto DT, Zheng Y, Wittner BS et al. RNA-Seq of single prostate CTCs 
implicates noncanonical Wnt signaling in antiandrogen resistance. Science 2015; 
349: 1351-1356. 
5. Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of 
advanced prostate cancer. Cell 2015; 161: 1215-1228. 
6. Grasso CS, Wu YM, Robinson DR et al. The mutational landscape of lethal 
castration-resistant prostate cancer. Nature 2012; 487: 239-243. 
7. Wang L, Dehm SM, Hillman DW et al. A Prospective Genome-Wide Study 
of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation 
and Increased Cell Cycle Proliferation with Primary Resistance to Abiraterone 
Acetate-Prednisone. Ann Oncol 2017. 
8. Richards J, Lim AC, Hay CW et al. Interactions of abiraterone, eplerenone, 
and prednisolone with wild-type and mutant androgen receptor: a rationale for 
increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012; 
72: 2176-2182. 
9. Izumchenko E, Paz K, Ciznadija D et al. Patient-derived xenografts 
effectively capture responses to oncology therapy in a heterogeneous cohort of 
patients with solid tumors. Ann Oncol 2017; 28: 2595-2605. 
10. Saeed K, Rahkama V, Eldfors S et al. Comprehensive Drug Testing of 
Patient-derived Conditionally Reprogrammed Cells from Castration-resistant 
Prostate Cancer. Eur Urol 2017; 71: 319-327. 
11. Aran D, Camarda R, Odegaard J et al. Comprehensive analysis of normal 
adjacent to tumor transcriptomes. Nat Commun 2017; 8: 1077. 
12. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin 
signalling prevents anti-tumour immunity. Nature 2015; 523: 231-235. 
13. Linch M, Goh G, Hiley C et al. Intratumoural evolutionary landscape of 
high-risk prostate cancer: the PROGENY study of genomic and immune 
parameters. Ann Oncol 2017; 28: 2472-2480. 
14. Francis JC, Thomsen MK, Taketo MM, Swain A. beta-catenin is required for 
prostate development and cooperates with Pten loss to drive invasive carcinoma. 
PLoS Genet 2013; 9: e1003180. 






























































15. Conteduca V, Wetterskog D, Sharabiani MTA et al. Androgen receptor 
gene status in plasma DNA associates with worse outcome on enzalutamide or 
abiraterone for castration-resistant prostate cancer: a multi-institution 
correlative biomarker study. Ann Oncol 2017; 28: 1508-1516. 
16. Antonarakis ES, Lu C, Luber B et al. Clinical Significance of Androgen 
Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men 
With Metastatic Castration-Resistant Prostate Cancer Treated With First- and 
Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology 2017; 
35: 2149-2156. 
17. Scher HI, Lu D, Schreiber NA, et al. Association of ar-v7 on circulating 
tumor cells as a treatment-specific biomarker with outcomes and survival in 
castration-resistant prostate cancer. JAMA Oncology 2016; 2: 1441-1449. 
 
Page 4 of 4Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
